Macquarie cuts Cosmos stock rating, raises price target

Published 15/04/2025, 06:28
Macquarie cuts Cosmos stock rating, raises price target

On Tuesday, Macquarie analysts adjusted their outlook on Cosmos Pharmaceuticals Corp. (3349:JP) (OTC: CSMYF), downgrading the stock to Neutral from Outperform, while simultaneously raising the price target to JPY8,000.00 from JPY7,600.00. This decision reflects a tempered view of the company’s growth prospects despite a recent increase in its share price.

The analysts at Macquarie cited the limited upside potential for Cosmos following its recent share price appreciation as the primary reason for the downgrade. They anticipate that Cosmos will exhibit strong earnings growth in the fiscal year ending May 2025, propelled by an improved gross profit margin, which is attributed to the company’s relaxed Every Day Low Price (EDLP) strategy.

The revised earnings per share (EPS) forecast from Macquarie takes into account the robust earnings growth that Cosmos is expected to achieve. However, the analysts express caution regarding the sustainability of gross profit margin expansion, considering the inherent challenges faced by businesses operating with a discounter model.

Despite the potential for strong performance in the near term, Macquarie suggests that further margin growth could be challenging. The analysts emphasize the importance of Cosmos enhancing its scale to maintain competitive pricing, which is crucial for increasing market share and strengthening its position as a competitive discounter in the industry.

The new price target of JPY8,000.00 reflects Macquarie’s updated expectations for Cosmos’s financial performance, despite the adjustment in the stock’s rating. The analysts’ outlook indicates a belief in the company’s ability to grow but also signals caution as the business moves forward in an increasingly competitive landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.